AlphaStocks
5.3
Consider Buy

Indivior Pharmaceuticals, Inc. (INDV)

As of Sep 20, 2026, Indivior Pharmaceuticals, Inc. (INDV) scores 5.3/10 on AlphaStocks' five-model composite, #89 of 168 Health Care stocks. At $35, INDV trades 17% below its model fair value of $42.

Health Care / Pharmaceuticals

S&P SmallCap 600

$34.91

Below average on several measures. Research carefully.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#89out of 168 in Health Care

Is Indivior Pharmaceuticals, Inc. a Good Investment in 2026?

Indivior Pharmaceuticals, Inc. (INDV) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model is the most favorable, rating Indivior Pharmaceuticals, Inc. as Neutral. However, the Graham model rates it Caution. Indivior Pharmaceuticals, Inc. currently trades 17% below its estimated fair value of $42. Indivior Pharmaceuticals, Inc. ranks #89 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E21.3ROE-71.3Market Cap5B

Estimated Fair Value

$42.1317% below

Trading below estimated fair value. EPS grew 3017% year-over-year. P/E of 21x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Neutral

Earnings yield 4.9% · ROC 26%

Frequently Asked Questions

Is Indivior Pharmaceuticals, Inc. (INDV) a good investment?
As of Sep 20, 2026, Indivior Pharmaceuticals, Inc. (INDV) scores 5.3/10 on AlphaStocks' five-model composite, #89 of 168 Health Care stocks. At $35, INDV trades 17% below its model fair value of $42. That score is below average, suggesting caution.
What is Indivior Pharmaceuticals, Inc.'s Piotroski F-Score?
Indivior Pharmaceuticals, Inc.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is INDV overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $42, INDV appears undervalued. The stock currently trades 17% below its estimated fair value. Trading below estimated fair value. EPS grew 3017% year-over-year. P/E of 21x is moderate for this quality level.
How does INDV compare to other Health Care stocks?
Indivior Pharmaceuticals, Inc. ranks #89 out of 168 stocks in the Health Care sector, placing it in the top 53% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about INDV?
AlphaStocks evaluates INDV using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 5.3/10.

Similar Stocks

AMPHLLYACAD

Compare INDV with

AMPH vs INDVINDV vs LLYACAD vs INDV

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer